Literature DB >> 10838256

Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene.

N Raben1, K Nagaraju, E Lee, P Plotz.   

Abstract

Glycogen storage disease type II (GSDII) is a recessively inherited disorder caused by defects in lysosomal acid alpha-glucosidase. In an attempt to reproduce the range of clinical manifestations of the human illness we have created null alleles at the acid alpha-glucosidase locus (GAA) with several gene targeting strategies. In each knockout strain, enzyme activity was completely abolished and glycogen accumulated at indistinguishable rates. The phenotypes, however, differed strikingly. Acid alpha-glucosidase deficiency on a 129xC57BL/6 background resulted in a severe phenotype with progressive cardiomyopathy and profound muscle wasting similar to that in patients with glycogen storage disease type II. On a 129/C57BL/6xFVB background, homozygous mutants developed a milder phenotype with a later age of onset. Females were more affected than males irrespective of genetic background. As in humans with glycogen storage disease type II, therefore, other genetic loci affect the phenotypic expression of a single gene mutation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10838256     DOI: 10.1016/s0960-8966(99)00117-0

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  17 in total

Review 1.  An emerging phenotype of central nervous system involvement in Pompe disease: from bench to bedside and beyond.

Authors:  Aditi Korlimarla; Jeong-A Lim; Priya S Kishnani; Baodong Sun
Journal:  Ann Transl Med       Date:  2019-07

2.  The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.

Authors:  William Coley; Sree Rayavarapu; Gouri S Pandey; Richard L Sabina; Jack H Van der Meulen; Beryl Ampong; Robert L Wortmann; Rashmi Rawat; Kanneboyina Nagaraju
Journal:  Arthritis Rheum       Date:  2012-11

3.  Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease.

Authors:  Nina Raben; Cynthia Schreiner; Rebecca Baum; Shoichi Takikita; Sengen Xu; Tao Xie; Rachel Myerowitz; Masaaki Komatsu; Jack H Van der Meulen; Kanneboyina Nagaraju; Evelyn Ralston; Paul H Plotz
Journal:  Autophagy       Date:  2010-11       Impact factor: 16.016

4.  Losartan decreases cardiac muscle fibrosis and improves cardiac function in dystrophin-deficient mdx mice.

Authors:  Christopher F Spurney; Arpana Sali; Alfredo D Guerron; Micaela Iantorno; Qing Yu; Heather Gordish-Dressman; Sree Rayavarapu; Jack van der Meulen; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  J Cardiovasc Pharmacol Ther       Date:  2011-03       Impact factor: 2.457

5.  Induction of tolerance to a recombinant human enzyme, acid alpha-glucosidase, in enzyme deficient knockout mice.

Authors:  Nina Raben; Kanneboyina Nagaraju; Alicia Lee; Nina Lu; Yesenia Rivera; Tejas Jatkar; John J Hopwood; Paul H Plotz
Journal:  Transgenic Res       Date:  2003-04       Impact factor: 2.788

6.  Functional and molecular effects of arginine butyrate and prednisone on muscle and heart in the mdx mouse model of Duchenne Muscular Dystrophy.

Authors:  Alfredo D Guerron; Rashmi Rawat; Arpana Sali; Christopher F Spurney; Emidio Pistilli; Hee-Jae Cha; Gouri S Pandey; Ramkishore Gernapudi; Dwight Francia; Viken Farajian; Diana M Escolar; Laura Bossi; Magali Becker; Patricia Zerr; Sabine de la Porte; Heather Gordish-Dressman; Terence Partridge; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  PLoS One       Date:  2010-06-21       Impact factor: 3.240

7.  Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression.

Authors:  Baodong Sun; Haoyue Zhang; Andrew Bird; Songtao Li; Sarah P Young; Dwight D Koeberl
Journal:  J Gene Med       Date:  2009-10       Impact factor: 4.565

8.  Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures.

Authors:  Christopher F Spurney; Heather Gordish-Dressman; Alfredo D Guerron; Arpana Sali; Gouri S Pandey; Rashmi Rawat; Jack H Van Der Meulen; Hee-Jae Cha; Emidio E Pistilli; Terence A Partridge; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  Muscle Nerve       Date:  2009-05       Impact factor: 3.217

9.  A Neuron-Specific Gene Therapy Relieves Motor Deficits in Pompe Disease Mice.

Authors:  Ni-Chung Lee; Wuh-Liang Hwu; Shin-Ichi Muramatsu; Darin J Falk; Barry J Byrne; Chia-Hao Cheng; Nien-Chu Shih; Kai-Ling Chang; Li-Kai Tsai; Yin-Hsiu Chien
Journal:  Mol Neurobiol       Date:  2017-09-11       Impact factor: 5.590

10.  Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy.

Authors:  Qing Yu; Arpana Sali; Jack Van der Meulen; Brittany K Creeden; Heather Gordish-Dressman; Anne Rutkowski; Sree Rayavarapu; Kitipong Uaesoontrachoon; Tony Huynh; Kanneboyina Nagaraju; Christopher F Spurney
Journal:  PLoS One       Date:  2013-06-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.